BioDelivery Sciences International, Inc.  

(Public, NASDAQ:BDSI)   Watch this stock  
Find more results for BDSI
-0.04 (-1.61%)
Oct 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.43 - 2.53
52 week 1.86 - 6.40
Open 2.48
Vol / Avg. 546,382.00/644,979.00
Mkt cap 131.41M
P/E     -
Div/yield     -
EPS -0.86
Shares 53.59M
Beta 1.46
Inst. own 66%
Nov 7, 2016
Q3 2016 BioDelivery Sciences International Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Oct 9, 2016
Dar Es Salaam Investment Bank PJSC Annual Shareholders Meeting
Sep 27, 2016
BioDelivery Sciences International Inc at Ladenburg Thalmann Healthcare Conference
Sep 21, 2016
BioDelivery Sciences International Inc at Aegis Capital Growth Conference
Sep 14, 2016
BioDelivery Sciences International Inc at Credit Suisse Small & Mid Cap Conference
Sep 13, 2016
BioDelivery Sciences International Inc at Rodman & Renshaw Global Investment Conference - Webcast
Aug 9, 2016
Q2 2016 BioDelivery Sciences International Inc Earnings Release
Aug 9, 2016
Q2 2016 BioDelivery Sciences International Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -329.46% -78.11%
Operating margin -311.63% -72.94%
EBITD margin - -70.25%
Return on average assets -78.72% -39.32%
Return on average equity -499.93% -87.52%
Employees 40 -
CDP Score - -


4131 Parklake Avenue, Suite 225
United States - Map
+1-919-5829050 (Phone)
+1-919-5829051 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Officers and directors

Frank E. O'Donnell Jr. Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark A. Sirgo President, Chief Executive Officer, Vice Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ernest R. De Paolantonio CPA Chief Financial Officer, Treasurer, Secretary
Age: 62
Bio & Compensation  - Reuters
Niraj Vasisht Senior Vice President, Chief Technology Officer
Bio & Compensation  - Reuters
Albert J. Medwar Senior Vice President - Corporate and Business Development
Bio & Compensation  - Reuters
Stephana E. Patton Ph.D. J.D. Vice President, General Counsel
Bio & Compensation  - Reuters
Sarah DeRossett Vice President - Clinical Research and Medical Affairs
Bio & Compensation  - Reuters
Joseph Lockhart Vice President - Manufacturing and Supply Chain
Bio & Compensation  - Reuters
William B. Stone Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Timothy C. Tyson Director
Age: 62
Bio & Compensation  - Reuters